Assessing the Influence of Proton Pump Inhibitors on Clinical Outcomes in Hormone Receptor-Positive Metastatic Breast Cancer Patients Receiving CDK4/6 Inhibitors: Evidence from a Ribociclib-Dominant Cohort. The gene discussed is CDK4; the disease is breast carcinoma.